Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Deferring PCI before TAVR shows comparable outcomes in elderly patients

29

Mar 2026

Deferring PCI before TAVR shows comparable outcomes in elderly patients

Older patients with coronary artery disease scheduled for transcatheter aortic valve replacement (TAVR) had comparable outcomes regardless of whether they underwent percutaneous coronary intervention (PCI) before TAVR, according to findings from the PRO-TAVI study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Transcatheter valve-in-valve procedure improves short-term outcomes in high-risk patients

29

Mar 2026

Transcatheter valve-in-valve procedure improves short-term outcomes in high-risk patients

In patients with a poorly functioning bioprosthetic mitral valve in the heart, a minimally invasive procedure to insert a new valve was associated with a lower rate of death or disabling stroke within one year, compared with patients who underwent standard repeat mitral valve replacement surgery, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Parasites trigger a gut-to-brain signal that cuts food intake during infection

29

Mar 2026

Parasites trigger a gut-to-brain signal that cuts food intake during infection

Researchers found that intestinal tuft cells signal to crypt enterochromaffin cells by releasing acetylcholine, triggering serotonin release and activating a gut-to-brain vagal pathway during type 2 inflammation. This sustained signalling, rather than the initial acute response, was linked to reduced food intake in mouse models of parasitic infection.

Minimally invasive valve repair lowers hospitalizations in heart failure patients

29

Mar 2026

Minimally invasive valve repair lowers hospitalizations in heart failure patients

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received optimal medical therapy plus a minimally invasive procedure using a clip to repair the valve were significantly less likely to die, have a heart attack or stroke and 40% less likely to be hospitalized for heart failure compared with similar patients who were randomly assigned to optimal medical therapy alone.

New drug sotatercept shows benefit in CpcPH-HFpEF patients

29

Mar 2026

New drug sotatercept shows benefit in CpcPH-HFpEF patients

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and vascular health after taking the drug sotatercept, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.